The stock of Viking Therapeutics Inc (VKTX) has gone down by -1.74% for the week, with a -5.17% drop in the past month and a -27.05% drop in the past quarter. The volatility ratio for the week is 4.73%, and the volatility levels for the past 30 days are 5.19% for VKTX. The simple moving average for the past 20 days is -6.93% for VKTX’s stock, with a -24.61% simple moving average for the past 200 days.
Is It Worth Investing in Viking Therapeutics Inc (NASDAQ: VKTX) Right Now?
Company’s 36-month beta value is 0.88.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 6 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VKTX is 108.05M, and currently, short sellers hold a 16.73% ratio of that floaft. The average trading volume of VKTX on December 17, 2024 was 4.09M shares.
VKTX) stock’s latest price update
The stock price of Viking Therapeutics Inc (NASDAQ: VKTX) has plunged by -0.45 when compared to previous closing price of 47.23, but the company has seen a -1.74% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-12-16 that NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. (“Viking” or the “Company”) (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Analysts’ Opinion of VKTX
B. Riley Securities, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $109. The rating they have provided for VKTX stocks is “Buy” according to the report published on November 22nd, 2024.
H.C. Wainwright gave a rating of “Buy” to VKTX, setting the target price at $102 in the report published on November 04th of the current year.
VKTX Trading at -20.59% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.70% of loss for the given period.
Volatility was left at 5.19%, however, over the last 30 days, the volatility rate increased by 4.73%, as shares sank -3.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.17% lower at present.
During the last 5 trading sessions, VKTX fell by -1.46%, which changed the moving average for the period of 200-days by -48.38% in comparison to the 20-day moving average, which settled at $50.52. In addition, Viking Therapeutics Inc saw 152.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from MACARTNEY LAWSON, who sale 2,000 shares at the price of $68.67 back on Nov 08 ’24. After this action, MACARTNEY LAWSON now owns 47,965 shares of Viking Therapeutics Inc, valued at $137,333 using the latest closing price.
LAWSON MACARTNEY, the Director of Viking Therapeutics Inc, proposed sale 2,000 shares at $68.67 during a trade that took place back on Nov 08 ’24, which means that LAWSON MACARTNEY is holding shares at $137,333 based on the most recent closing price.
Stock Fundamentals for VKTX
Current profitability levels for the company are sitting at:
- -307.27 for the present operating margin
- 0.29 for the gross margin
The net margin for Viking Therapeutics Inc stands at -227.41. The total capital return value is set at -0.15. Equity return is now at value -15.50, with -15.02 for asset returns.
Based on Viking Therapeutics Inc (VKTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -154.69. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -1395.5.
Currently, EBITDA for the company is -100.83 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 11983.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 36.47.
Conclusion
In a nutshell, Viking Therapeutics Inc (VKTX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
